Understanding and Managing AI Bias in Medical Devices

Artificial intelligence and machine learning are increasingly influencing how medical devices detect disease, evaluate risk, monitor patients, and support clinical decisions. These capabilities can improve efficiency and provide insights that are difficult to achieve through conventional approaches. They can also introduce new sources of risk.

An AI-enabled device may demonstrate strong overall performance while producing meaningfully different results for certain patient populations. Unrepresentative datasets, historical healthcare disparities, design decisions, and differences between development and real-world environments can all contribute to biased performance. For medical device manufacturers, AI bias is therefore more than a question of algorithmic fairness.

What Is AI Bias in Medical Devices?

AI bias occurs when an algorithm systematically produces incorrect results or meaningfully different performance for certain populations, circumstances, or environments.

Bias can originate in development data. Historical healthcare datasets may reflect disparities in access, diagnosis, treatment, and data collection. If those patterns enter training data without adequate evaluation, an AI model may reproduce or amplify them.

A widely discussed 2019 study, for example, identified racial bias in a healthcare risk-prediction algorithm that used healthcare costs as a proxy for healthcare needs. Because spending did not accurately represent illness burden, the algorithm underestimated the needs of certain patients.

Relevant factors may include age, sex, race or ethnicity, skin tone, disease prevalence, geography, or clinical setting, depending on the device. The objective for manufacturers is to understand whether performance differences could affect safety or effectiveness for the intended patient population.

Where Can Bias Enter the AI/ML Development Lifecycle?

AI bias can emerge throughout medical device development:

• Data collection and selection are important starting points. Underrepresented populations or data drawn from limited clinical environments may produce models that perform less reliably for certain groups. Appropriately diverse training data can help reduce this risk.
• Data labeling and model development introduce additional concerns. Labels can contain subjective judgments, while design decisions or proxy variables can unintentionally encode demographic or socioeconomic differences. Models may even learn demographic attributes or correlated characteristics rather than clinically meaningful indicators.
• Testing and validation can conceal these problems when teams rely heavily on aggregate performance. A model may achieve strong overall results while demonstrating meaningful subgroup differences. Validation populations may also fail to represent the diversity of real-world patients and clinical environments.

Bias can continue after deployment. Changes in patient populations, workflows, sensors, input data, or clinical environments can degrade performance, making appropriate post-deployment monitoring important.

Why Is AI Bias a Regulatory and Risk Management Concern?

Algorithmic bias can produce direct clinical consequences. Diagnostic systems trained on unrepresentative data may contribute to misdiagnosis or delayed treatment, while risk-prediction tools could incorrectly prioritize certain populations. Measurement and sensor limitations may create additional performance differences across demographic groups.

Automation bias creates another concern when clinicians place excessive confidence in AI-generated recommendations. If an algorithm performs poorly for a particular population, over-reliance on its output can compound the problem.

Manufacturers should therefore evaluate bias through their broader medical device risk management framework. When differential performance could contribute to a hazardous situation, that relationship should be identified, evaluated, controlled where appropriate, and supported by evidence.

Transparency is also critical. Opaque AI systems can make findings difficult to interpret or verify. Regulatory evidence should provide sufficient clarity around datasets, performance, limitations, risk controls, and validation to support conclusions regarding device safety and effectiveness.

How Can Medical Device Manufacturers Identify and Mitigate AI Bias?

Bias mitigation begins with clearly defining the intended population and use environment. Manufacturers can then determine whether development and validation datasets adequately represent those conditions.

Dataset provenance, inclusion and exclusion criteria, demographic composition, and known limitations should be documented. Teams should also identify clinically relevant subgroups and evaluate appropriate performance metrics across them.

When meaningful disparities emerge, mitigation strategies may include incorporating more representative data, refining model features, or using subgroup robustness methods. Depending on the application, developers may consider distinct models for identifiable populations or group-adversarial approaches designed to reduce inappropriate reliance on demographic information.

No single technique provides a universal solution. Mitigation should be justified according to the device, dataset, intended population, and identified risks.

Periodic audits and postmarket monitoring can further help manufacturers determine whether performance remains appropriate as the device encounters real-world populations and environments.

What Should AI Bias Documentation Demonstrate?

Regulatory documentation should make it possible to understand how potential bias was identified, evaluated, and addressed.

Manufacturers should establish where development and validation data originated, which populations are represented, why the datasets are appropriate, which subgroups were evaluated, and which performance metrics were selected. When differences are identified, documentation should explain their clinical significance and any resulting mitigations, limitations, or risk controls.

Dataset documentation, performance analyses, risk management files, intended use, labeling, and submission materials should all support consistent conclusions.

Sophisticated data science alone does not create defensible regulatory evidence. Reviewers need to follow the rationale connecting the data, model behavior, identified risks, validation results, and conclusions.

What Are Common Mistakes When Addressing AI Bias?

A large dataset is not necessarily a representative dataset. Manufacturers can also create compliance gaps by evaluating only aggregate performance, choosing subgroup analyses without clinical justification, identifying data limitations too late, or failing to connect bias findings with risk management.

Bias evaluation should not end at regulatory submission. Model performance can change when a device encounters different populations, workflows, equipment, or clinical environments. Appropriate lifecycle monitoring helps manufacturers identify emerging disparities and performance degradation.

How Can Quality Commercial Consultants Support AI/ML Medical Device Compliance?

Organizations developing AI/ML-enabled medical devices often possess sophisticated technical capabilities. The challenge is translating that work into evidence that clearly addresses regulatory expectations.

Quality Commercial Consultants (QCC) helps medical device manufacturers, SaMD developers, and digital health organizations evaluate existing AI/ML development evidence and identify regulatory gaps. Support can include:

• AI/ML regulatory gap assessments
• Dataset and data-provenance documentation
• Bias and subgroup analysis strategy
• Performance evidence review
• Risk management alignment
• Traceability
• Regulatory documentation
• FDA submission support

Rather than unnecessarily rebuilding mature engineering processes, QCC works with existing technical artifacts and development environments to help organizations establish clear, traceable, and defensible regulatory evidence.

Build Bias Evaluation into AI Medical Device Development

AI bias is most effectively addressed throughout development rather than as a final check before submission. Considering dataset composition, intended populations, subgroup performance, clinical consequences, and risk early gives manufacturers greater flexibility to address limitations before they become costly development or regulatory issues.

For organizations developing AI-enabled medical devices and SaMD, QCC can help evaluate existing evidence, identifying gaps and establishing a practical strategy for demonstrating that AI performance is appropriately characterized and supported for regulatory review.